Drug Interactions between Caltrate and Grisactin 500
This report displays the potential drug interactions for the following 2 drugs:
- Caltrate (calcium carbonate)
- Grisactin 500 (griseofulvin)
Interactions between your drugs
No interactions were found between Caltrate and Grisactin 500. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Caltrate
A total of 223 drugs are known to interact with Caltrate.
- Caltrate is in the following drug classes: antacids, minerals and electrolytes.
- Caltrate is used to treat the following conditions:
Grisactin 500
A total of 274 drugs are known to interact with Grisactin 500.
- Grisactin 500 is in the drug class miscellaneous antifungals.
- Grisactin 500 is used to treat the following conditions:
Drug and food interactions
griseofulvin food
Applies to: Grisactin 500 (griseofulvin)
MONITOR: Isolated case reports have suggested that the ingestion of alcohol during griseofulvin therapy may rarely cause disulfiram-like reactions, flushing, tachycardia, or increased effects of alcohol. The mechanism is unknown.
MANAGEMENT: Patients should be advised of the possibility of increased adverse effects or a disulfiram-like reaction.
References (3)
- "Product Information. Grifulvin V (griseofulvin)." Ortho McNeil Pharmaceutical
- (2002) "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation
- Cerner Multum, Inc. "Australian Product Information."
calcium carbonate food
Applies to: Caltrate (calcium carbonate)
ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
References (6)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
- Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.